Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Effectiveness of Povorcitinib for Adults with Nonsegmental Vitiligo

Fast replyInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a medication called Povorcitinib in individuals with a skin condition known as vitiligo. Vitiligo is a condition where patches of skin lose their color, leading to lighter areas on the body. The study will specifically look at a type of vitiligo called nonsegmental vitiligo, which is the most common form and can appear on both sides of the body. Participants in the study will receive either Povorcitinib or a placebo, which is a substance with no active medication, to compare the effectiveness of the treatment.

The purpose of the study is to evaluate how well Povorcitinib works in improving the skin condition over a period of 52 weeks. Participants will take the medication in the form of a tablet by mouth. Throughout the study, researchers will monitor changes in the skin, particularly looking for improvements in the color of the skin on the face and body. The study aims to see if participants experience at least a 75% improvement in their skin condition by the end of the study period.

Participants will be involved in the study for about a year, during which they will have regular check-ups to assess their progress. The study will help determine if Povorcitinib is a safe and effective treatment option for people with nonsegmental vitiligo. This research could potentially lead to new treatment options for those affected by this skin condition.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the participant will be required to sign a consent form, confirming understanding and willingness to participate.

    The participant must be at least 18 years old and have a clinical diagnosis of nonsegmental vitiligo.

  2. Step 2

    Discontinuation of current treatments

    The participant must stop using any treatments or procedures for vitiligo from the start of the study until the final safety follow-up visit.

  3. Step 3

    Medication administration

    The participant will receive either Povorcitinib or a placebo in the form of a tablet, taken orally.

    The treatment will last for 52 weeks.

  4. Step 4

    Regular assessments

    Throughout the study, the participant will undergo regular assessments to monitor the progress of the treatment.

    These assessments will include photography to document changes in vitiligo.

  5. Step 5

    Evaluation of treatment effectiveness

    The main goal is to evaluate the effectiveness of Povorcitinib compared to the placebo after 52 weeks.

    The primary measure of success is achieving at least a 75% improvement in the Face Vitiligo Area Scoring Index (F-VASI75).

  6. Step 6

    Secondary evaluations

    Secondary evaluations include changes in the Total Body Vitiligo Area Scoring Index (T-VASI) and the Vitiligo Noticeability Scale (VNS).

    These evaluations will also occur at the 52-week mark.

Who can join the trial?

6 criteria

  • Ability to understand and willingness to sign a written consent form for the study.
  • Must be at least 18 years old at the time of giving consent.
  • Have a clinical diagnosis of nonsegmental vitiligo, which is a type of skin condition that causes loss of skin color in patches.
  • Agree to stop using all treatments for vitiligo from the start of the study until the final safety follow-up visit.
  • Willingness to avoid becoming pregnant or fathering children during the study, following specific guidelines.
  • Willing and able to follow the study rules and procedures, including having photographs taken as part of the study.

Who cannot join the trial?

7 criteria

  • Participants with any other skin condition that might interfere with the study.
  • Individuals who have used certain medications that could affect the study results.
  • People with a history of severe allergic reactions to similar treatments.
  • Participants with any serious health conditions that could make the study unsafe for them.
  • Individuals who are pregnant or breastfeeding.
  • People who have participated in another clinical trial recently.
  • Participants who are unable to follow the study procedures or attend the required visits.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Povorcitinib is a medication being studied for its effectiveness in treating nonsegmental vitiligo, a condition that causes loss of skin color in patches. The trial aims to determine how well this medication works over a 52-week period. Participants in the study receive this medication to see if it can help improve their skin condition by restoring color to the affected areas.

What is already known about the treatment

Povorcitinib – Povorcitinib is administered orally and is currently being studied in clinical trials for its effectiveness in treating nonsegmental vitiligo, a condition characterized by loss of skin pigmentation. The medication is in the Phase 3 stage of clinical trials, indicating it is being evaluated for safety and efficacy before potential approval for widespread use. Povorcitinib works by inhibiting specific enzymes involved in the immune response, which may help restore skin color in affected areas. It is classified as a Janus kinase (JAK) inhibitor, a type of medication that targets pathways involved in inflammation and immune regulation.

Investigated diseases

Vitiligo – Vitiligo is a skin condition characterized by the loss of pigment, resulting in white patches on various parts of the body. It occurs when the cells responsible for skin color, called melanocytes, are destroyed. The progression of vitiligo can vary; some people may experience slow and gradual spreading of the patches, while others might see rapid changes. The condition can affect any skin area, including the face, hands, and feet, and may also impact hair and the inside of the mouth. The exact cause of vitiligo is not fully understood, but it is believed to involve genetic, autoimmune, and environmental factors. It is not contagious and does not cause physical discomfort, but it can have significant psychological and social effects.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-505782-86-00Protocol codeINCB 54707-303Estimated enrolment444 patientsSponsorIncyte Corp.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).